Synonyms: (2E)-N-(4-(3-chloro-4-fluoroanilino)-7-(((3S)-oxolan-3-yl)oxy)quinoxazolin-6-yl)-4-(dimethylamino)but-2-enamide; afatinib; BIBW2992; X7366; A15572; D09724; Q-3651; AB01565886_02; 081B182; SR-01000941576; SR-01000941576-1; 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino; BRD-K66175015-001-01-7; BIBW2992 MA2; I14-17009; (2E)-N-[4-(3-Chloro-4-fluoroanilino)-7-[[(3S)-oxolane-3-yl]oxy]quinazoline-6-yl]-4-(dimethylamino)-2-buteneamide; (E)-4-dimethylamino-but-2-enoic acid-(4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6yl)-amide; (E)-N-[4-(3-chloro-4-fluoro-anilino)-7-[(3S)-tetrahydrofuran-3-yl]oxy-quinazolin-6-yl]-4-(dimethylamino)but-2-enamide; (S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3''S'')-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; Gilotrif; Afatinib maleate; Afatinib [USAN]; Tovok (TN); Gilotrif; AFATINIB DIMALEATE; BIBW2992 Afatinib; Tovok, BIBW2992; EGFR inhibitor 2nd gens; D05UFG; cc-109; BIBW 2992MA2; BIBW-2992MA2; BIBW2992 MA2; BIBW 2992 MA2; Afatinib; BIBW-2992-MA2; Afatinib, 99% - 25MG 25mg; ACN-036294; CS-T-01429; CID10184653; CID 10184653; PD0332991; A8247; A10141; C522924; 439081-18-2; D000077716; 0WM; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)- 6-quinazolinyl)-4-(dimethylamino)-, (2E)-; 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2e)-, (2Z)-2-butenedioate (1:2); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one 2-hydroxy-ethanesulfonic acid (1:1); 850140-72-6; BIBW2992; Tovok; BIBW 2992; Tomtovok; afatinib dimaleate; BIBW-2992; Afatinib (BIBW2992); (S,E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; afatinibum; UNII-41UD74L59M; Tovok,BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; (S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-Butenamide; CHEMBL1173655; afatinib maleate; CHEBI:61390; 41UD74L59M; S1011; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-oxolan-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; (S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; J-500781; J-502300; (2e)-n-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3s)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-2-butenamide; 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; C24H25ClFN5O3; BIBW 2992; Afatinib [USAN:INN]; (E)-4-dimethylamino-but-2-enoic acid-(4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6-yl)-amide; (E)-4-Dimethylamino-but-2-enoic acid-[4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6-yl]-amide; 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-, (2E)-; Afatinib Impurity G; Afatinib, Free Base; BIBW2992,Afatinib; PubChem22403; Afatinib (USAN/INN); BIBW2992 - Afatinib; BIBW 2992 MA2; Tovok|||BIBW 2992; (2E)-N-(4-(3-chloro-4-fluoroanilino)-7-(((3S)-oxolan-3-yl)oxy)quinoxazolin-6-yl)-4-(dimethylamino)but-2-enamide; MLS006010000; BIFK0010; GTPL5667; CHEBI:94698; EX-A065; QCR-169; ULXXDDBFHOBEHA-CWDCEQMOSA-N; ZX-AFC000305; BIBW 2992MA2; BCPP000338; (R,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; AMX10177; AOB87785; BCP01779; ZINC3976838; BIBW2992/Tovok,BIBW-2992; 3123AC; ABP000859; AN-537; BIBW-2992; BDBM50322823; MFCD12407405; NSC750691; Afatinib(cis-trans isomerismtautomers); AKOS015850681; AKOS015904219; AKOS025149636; BCP9000407; DB08916; EX-8656; BIBW-2992-MA2; NSC-750691; PB28439; RL05240; NCGC00185000-01; AC-26079; AC-27018; AJ-47553; AM808098; DS-14172; SC-66830; BIBW-2992MA2; SC-87772; SMR004701084; AB0033685; AX8164181; AX8210970; TC-162525; TC-163608; FT-0083487; ST24036355; SW219248-1;